Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE)

PHASE3CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

February 19, 2020

Study Completion Date

February 19, 2020

Conditions
Ehlers-Danlos Syndrome, Vascular Type
Interventions
DRUG

Irbesartan

Irbesartan: 150 or 300 mg o.d. The up-titration of irbesartan from 150 mg to 300 mg o.d. occur during the first 8 weeks following randomization

DRUG

Placebo

Placebo o.d. to match 150mg or 300mg irbesartan tablets

Trial Locations (15)

13385

AP-HM - Hopital de la Timone, Marseille

14033

CHU DE CAEN - Hopital Cote de Nacre, Caen

31059

CHU DE TOULOUSE - Hopital Purpan, Toulouse

CHU DE TOULOUSE - Hopital Rangueil, Toulouse

33075

CHU DE BORDEAUX - Hopital Saint Andre, Bordeaux

34295

CHU DE MONTPELLIER - Hopital Saint Eloi, Montpellier

37044

CHU DE TOURS - Hopital Trousseau, Chambray-lès-Tours

38043

CHU DE GRENOBLE - Hopital Albert Michallon, Grenoble

CHU DE GRENOBLE - Hopital Couple Enfant, Grenoble

44300

CHU DE NANTES - Hopital Hotel-Dieu, Nantes

54500

CHRU DE NANCY - Institut Lorrain du Coeur et des Vaisseaux, Vandœuvre-lès-Nancy

59000

CHRU DE LILLE - Hopital Claude Huriez, Lille

69003

CHU DE LYON - Hopital Edouard Herriot, Lyon

69500

CHU DE LYON - Hopital Femme Mere Enfant, Bron

75015

AP-HP - Hopital Europeen Georges-Pompidou, Paris

All Listed Sponsors
collaborator

Ministry of Health, France

OTHER_GOV

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02597361 - Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE) | Biotech Hunter | Biotech Hunter